Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California....
+See More2027-11-23 09:24:00 Tuesday ET
AYA fintech network platform provides proprietary alpha stock signals and personal finance tools for stock market investors. As of August 2026, we have u
2018-02-11 07:30:00 Sunday ET
President Trump unveils his ambitious $1.5 trillion public infrastructure plan. Trump proposes offering $100 billion in federal incentives to encourage stat
2018-01-19 11:32:00 Friday ET
Most major economies grow with great synchronicity several years after the global financial crisis. These economies experience high stock market valuation,
2023-06-19 10:31:00 Monday ET
A brief biography of Dr Andy Yeh (PhD, MFE, MMS, BMS, FRM, and USPTO patent accreditation) Dr Andy Yeh is responsible for ensuring maximum sustainable me
2025-06-13 08:23:00 Friday ET
What are the mainstream legal origins of President Trump’s new tariff policies? We delve into the mainstream legal origins of President Trump&rsquo
2022-05-15 10:29:00 Sunday ET
Innovative investment theory and practice Corporate investment can be in the form of real tangible investment or intangible investment. The former conce